CD4 and ovarian carcinoma: In contrast, the presence of the CD4-positive regulatory subtype of T lymphocytes (Treg; CD4+CD25+FoxP3+) seems to reduce tumour-specific immunity and results in a poorer survival of patients with ovarian carcinomas (Curiel et al, 2004).